UNIVERSITY INSTITUTE OF ENGINEERING & TECHNOLOGY
PANJAB UNIVERSITY, CHANDIGARH - 160014

1. **Name** : Prasant Kumar Nanda
2. **Designation** : Assistant Professor
3. **Date of Birth** : 11th July 1977
4. **Contact Number** : 8284854681
5. **E-mail id** : pknanda@pu.ac.in

6. Educational background

Degree	Institute Name	Year of Passing
B.Sc	Utkal University	1997
M. Sc.	Utkal University	2000
Ph. D	IIT Kharagpur	2007

7. Professional background

Designation	**Institute Name**	**Duration**
Post-Doctoral Research Associate	University of Missouri-Columbia, USA	Oct 2006-March 2012
Assistant Professor (Chemistry)	Lovely Professional University	August 2012-April 2013

8. Main area of work: Inorganic Chemistry, Nuclear Medicine

9. Awards/Honors/Fellowship etc.:

2001 Qualified All India Graduate Aptitude Test in Engineering (GATE)

2003 Qualified CSIR/JRF Fellowship

2009 Young Investigator's Award from the Society of Nuclear Medicine

2010 Radiopharmaceutical Science Young Investigator Award from Society of Nuclear Medicine

2011 People' Choice Award for Young Investigator from Missouri Foundation of Medical Research

9. Scientific Contributions:

Papers published in International Journal	24
Papers published in national Journal	01
Papers published in International conference	12
Papers published in national conference	01
Papers presented in International/National conferences	12
Research Projects	01
Books/Book Chapters Published	02
Participation in International/ National Conferences/symposium etc.	22

10. Highlight of Research Work:

My research work focuses design, synthesis, characterization of novel ligand framework with development and standardization of new reaction pathways for the syntheses of exogenous bridge controlled novel di- and tetranuclear metal complexes. I am also interested in the development of site-directed molecular imaging agents for human cancer through monomeric/multimeric peptide conjugates and functionalized nanoparticles. This will provide a great opportunity to use peptide receptor targeted therapy as a highly selective treatment strategy for tumor targeting or as a mechanism for this treatment strategy to complement traditional, clinically-useful chemotherapeutic regimens of treatment. This research application provides rationale toward the design and development of new diagnostic/therapeutic radiopharmaceuticals for the early detection or treatment of human cancer.

Signature